10 years after the UN general assembly special session on drugs
PLoS Med 10(1): e1001366. https://doi.org/10.1371/journal.pmed.1001366
Published: January 8, 2013
DHS Working Papers No. 114
Cardiovascular diseases (CVDs) have collectively remained the leading causes of death worldwide and substantially contribute to loss of ...="attribute-to-highlight medbox">health and excess health system costs. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study has tracked trends in death and disability since 1990 and has provided an updated perspective on the status of cardiovascular health globally, regionally, and nationally.
more
Vanquishing violence and vulnerability in humanitarian settings
Background paper for the joint African Union–UNAIDS (in capacity of serving
Chair of... H6) high-level side event at the 73rd United Nations General Assembly,
24 September 2018, at UNHQ, Conference Room 3
more
14 January 2021
This practical guide can be used to help countries monitor and analyse the impact of COVID-19 on essential health ...ribute-to-highlight medbox">services to inform planning and decision-making. It provides practical recommendations on how to use key performance indicators to analyse changes in access to and delivery of essential health services within the context of the COVID-19 pandemic; how to visualize and interpret these data; and how to use the findings to guide modifications for safe delivery of services and transitioning towards restoration and recovery. The guide focuses on existing indicators and data that are captured in routine reporting systems and how they can be used by national and subnational authorities to understand specific contexts, challenges and bottlenecks. This guide supports Maintaining essential health services: operational guidance for the COVID-19 context, which provides an integrated framework to guide countries in their efforts to reorganize, adapt and maintain safe delivery of high-priority essential health services within the context of the pandemic.
more
Depress Anxiety. 2018 March ; 35(3): 195–208. doi:10.1002/da.22711.
This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention ...x">and control programme. The guidance includes a step-by-step process to be followed after the decision has been made to specifically introduce and/or scale-up HPV virological testing for screening, which would be followed up with adequate management within the context of cervical cancer prevention
more